Treatment I

DRUG2 trials

Sponsors

Gilead Sciences, Sun Pharmaceutical Industries Limited

Conditions

Active Rheumatoid ArthritisChronic Lymphocytic Leukemia

Phase 1

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

CompletedNCT01841489

Gilead SciencesChronic Lymphocytic Leukemia

Start: 2013-05-31End: 2013-10-31Updated: 2014-02-07

Phase 3

To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

TerminatedNCT02534896

Sun Pharmaceutical Industries LimitedActive Rheumatoid Arthritis

Start: 2015-11-30End: 2018-06-30Updated: 2021-11-19